McKesson Corporation provides healthcare services in the United States and internationally.
$1,102.81+2.39%
报价 2026-11-13
市值
$127.33B
EV
$113.91B
PE (TTM)
24.9x
预期 PE (FY2027)
24.1x
52 周区间距高点 0.0%
$725.17$1,102.81
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-03 | 1.1x | 42.64 → 52.25（1.2x） | 21.1 |
| FY+32029-03 | 1.2x | 42.64 → 59.89（1.4x） | 18.4 |
毛利率 3% · TTM 收入 $418790M · 基数 EPS 42.64（调整后）
电话会信号
辅助标签Q2 20272026-11-04
上调指引
指引 上调
信心 5
分析师 4
“We are raising our fiscal 27 adjusted EPS guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.”
原文引用（1）
- 上调指引：we are raising our fiscal 27 adjusted earnings per diluted share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MCKMcKesson Corporation | $127.33B | +2.4% | +6.5% | 3.6% | 24.9x | 17.6x | 18.4x | |
| VRTXVertex Pharmaceuticals Incorporated | $136.56B | -0.7% | +10.6% | 86.3% | 29.0x | 23.5x | 42.6x | |
| MDTMedtronic plc | $131.58B | +1.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $129.66B | +1.8% | +4.6% | 67.7% | 16.5x | 10.5x | 14.0x | |
| SYKStryker Corporation | $117.88B | -0.9% | +7.0% | 63.5% | 39.2x | 24.7x | 25.8x | |
| SNYSanofi | $115.9B | -0.2% | – | 71.7% | 8.9x | 9.7x | – | |
| CVSCVS Health Corporation | $114.32B | -0.5% | +5.2% | 13.8% | 51.2x | 17.8x | 7.3x | |
| HCAHCA Healthcare, Inc. | $104.25B | -0.3% | +4.5% | 14.9% | 16.7x | 9.9x | 17.7x | |
| GSKGSK plc | $101.13B | +0.5% | – | 72.5% | 13.7x | 7.8x | – | |
| 同行中位数 | – | – | +6.1% | 65.6% | 20.5x | 12.7x | 17.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q2 2027 | 2026-06-30 Q1 2027 | 2026-03-31 Q4 2026 | 2025-12-31 Q3 2026 | 2025-09-30 Q2 2026 | 2025-06-30 Q1 2026 | 2025-03-31 Q4 2025 | 2024-12-31 Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $110.96B | $105.38B | $96.3B | $106.16B | $103.15B | $97.83B | $90.82B | $95.29B |
| Gross Margin | 3.6% | 3.5% | 4.2% | 3.5% | 3.4% | 3.4% | 3.2% | 3.4% |
| Operating Margin | 1.4% | 1.3% | 2.3% | 1.5% | 1.4% | 1.1% | 1.1% | 1.4% |
| Net Income | $1.22B | $614M | $1.68B | $1.19B | $1.11B | $784M | $1.26B | $879M |
| Diluted EPS | 10.44 | 5.15 | 13.71 | 9.59 | 8.92 | 6.25 | 10.01 | 6.94 |
| Operating Cash Flow | $3.07B | $-220M | $3.42B | $1.23B | $2.42B | $-918M | $7.75B | $-2.38B |